GB2310801A - Process for removing an organic solvent from lactide-glycoside copolymer microspheres - Google Patents
Process for removing an organic solvent from lactide-glycoside copolymer microspheres Download PDFInfo
- Publication number
- GB2310801A GB2310801A GB9704186A GB9704186A GB2310801A GB 2310801 A GB2310801 A GB 2310801A GB 9704186 A GB9704186 A GB 9704186A GB 9704186 A GB9704186 A GB 9704186A GB 2310801 A GB2310801 A GB 2310801A
- Authority
- GB
- United Kingdom
- Prior art keywords
- microspheres
- ethyl acetate
- lactide
- water
- poly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Description
TITLE OF THE INVENTION
PROCESS FOR REMOVING ORGANIC PHASE SOLVENT FROM
PLGA MICROSPHERES CONTAINING A LIPOPHILIC DRUG
BACKGROUND OF THE INVENTION
The present invention relates to a process of removing the organic solvent from PLGA microspheres. Micospheres made of poly(lactide-co-glycolide) have been widely studied for the delivery of drugs and biologicals. One of the most popular methods for preparing drug-containing microspheres involves the formation of an oil-in-water emulsion followed by solvent removal via an extraction/evaporation, henceforth referred to as the 'single emulsion process'. In this process, the suspension (after solvent extraction/evaporation and washing) is sometimes lyophilized with appropriate additives and packaged as a finished product. More often, wet microspheres are recovered from the suspension, dried and packaged.
Ordinarily an extended solvent extraction step followed by drying or other measures is required to provide PLGA microspheres which are suitable for use in pharmaceutical preparations. The present invention involves a minimum amount of organic solvent removal or extraction time, with up to about 95% removal occcuring essentially in a few minutes.
SUMMARY OF THE INVENTION
In one aspect of the invention, a process for removing the organic phase solvent from poly(lactide-co-glycolide) microspheres containing a lipophilic drug compound is disclosed. The process compnses: forming poly(lactide-co-glycolide) microspheres in an ethyl acetate/water two phase system;
emulsifying the two phase system at approximately a 1:1 to about 3:1 ratio of water to ethyl acetate continuously to form microspheres;
and continuously introducing the emulsion into a water reservoir which is less than about 15-20 times the volume of the cumulative volume of the emulsion, effective for extracting the ethyl acetate from the microspheres.
In a further aspect of the invention, the process is as described above, wherein the water reservoir is effective for extracting up to about 95% of the ethyl acetate from the microspheres.
In yet another aspect of the invention, the process is as described above wherein the lipophilic drug compound is selected from the group consisting of: avermectins, milbemycins, nodulisporic acid and derivatives thereof, fipronil and steroids.
BRIEF DESCRIPTION OF THE DRAWINGS
The invention is described in connection with the drawings appended hereto, of which:
Figure I is the isothermal drying curve of a wet microsphere cake.
DETAILED DESCRIPTION OF THE INVENTION
The following terms and definitions are applicable to the invention described herein unless otherwise indicated:
As used herein, the term "poly(lactide-co-glycolide)" is used in the conventional sense to refer to: poly(glycolic acid), poly-d, l-lactic acid, poly-l-lactic acid, copolymers of glycolic acid, l-lactic acid and d,l-lactic acid. Commercial vendors include Medisorb Technologies
International (MTI), Boeheringer Ingelheim and Birmingham Polymers.
Lipophilic drugs which are useful in the present invention include the following: avermectins, milbemycins, nodulisporic acid and derivatives thereof, fipronil and steroids. Generally, lipophilic drugs useful herein include those drugs which are water insoluble, and soluble in ethyl acetate and methylene chloride.
The emulsion that is continuously formed is introduced into a water reservoir as quickly as possible, preferably immediately. The water reservoir is up to about 15 to 20 times the cumulative volume of the emulsion.
Emulsifying agents which are useful in the present invention include: poly(vinyl alcohol), Tween 80, polysorbates and poloxamers.
The invention is further illustrated in connection with the following non-limiting example.
Materials
PLGA (8515, iv= 0.689 dL/g) was purchased from MTI (Cincinnati,
OH). Ethyl acetate and poly(vinyl alcohol) (88% hydrolyzed were supplied by Aldrich.
Procedure
Avermectins (1 part) and PLGA (1 part) were dissolved in ethyl acetate (8 parts) to form the "organic phase". Poly(vinyl alcohol) was dissolved in water (0.5%) to form the "aqueous phase".
The two phases were mixed and emulsified continuously using an on-line static mixer at -2:1 ratio (aqueous:organic) and the emulsion was introduced immediately into a water reservoir under gentle agitation. The water reservoir is up to about 15-20 times the cumulative volume of the emulsion and is maintained at approximately 10 C.
Extraction rate of ethvl acetate
Four batches of different sizes were made. The final ethyl acetate concentration in the water reservoir ranged from -1.6 to -5.0 wt%. As shown in Table 1, regardless of the batch size, approximately 90% of the solvent which was introduced via the oil-in-water emulsion was extracted into the water reservoir within 5 minutes. Longer extraction times removed marginally more solvent from the wet microspheres.
Since the yield of dry microspheres was greater than 95%, the wt% of ethyl acetate in the wet microspheres can be estimated from the data in Table 1. The estimates are shown in Table 2. Roughly 30 wt% of the wet microspheres is attributed to residual ethyl acetate.
Drying characteristics of wet microspheres
The isothermal drying curve of the wet cake is illustrated in
Figure 1. The TGA analysis was run at 35"C, with a dry-nitrogen flow rate of 10-20- cc/min. The volatile content of the microspheres can be lowered to less than 1 wt% in less than 15 min.
The total volatile content of the wet microspheres can also be determined from the drying curve. These data are summarized in
Table 3. The volatile content does not vary much with extraction time.
Comparing the data in Tables 2 and 3 one also finds that more than two thirds of the volatile content of the wet microspheres is indeed solvent, the rest is water.
Table 1
Percent Solvent Extracted into Aqueous Phase After Dispersion
Batch ID Time, mien A B C D 5 91% 90% 90% 92% 15 88% 90% 90% 92% 60 87% 90% 96% Average Solvent wt% in the Aqueous Phase 9.95 1.61 4.36 5.04 Table 2
Solvent content of wet microspheres recovered by filtration
(Calculated from solvent extraction data.)
Batch ID A B C D %Wt (wet-basis) 30 30 29 23 Table 3
Volatile content of wet microspheres recovered
at various times after dispersion
Time, min 10 24 38 60 %Wt (wet-basis) ~ 33 ~ ~ 35 ~ 31 38 When ethyl acetate was used as the solvent for the preparation of microspheres in the 'single emulsion process', around 90% of the solvent was extracted into the water reservoir within 5 min.
Prolonging the extraction did not significantly increase the extent of solvent removal from the wet microspheres.
The high volatility of ethyl acetate, the small size of the microspheres (volume-average diameter in the range of 50 to 120 micron), and the favorable external mass transfer used allows nearly complete drying of the microspheres (to < 1 wt%) within 15 min at 35"C.
While certain preferred embodiments are described herein in detail, numerous alternative embodiments are contemplated as falling within the invention.
Claims (5)
1. A process for removing an organic phase solvent from poly(lactide-co-glycolide) microspheres containing a lipophilic drug compound, which comprises:
combining poly(lactide-co-glycolide) and a lipophilic drug compound in an ethyl acetate/water two phase system;
emulsifying the two phase system at approximately a 1:1 to about 3:1 ratio of water to ethyl acetate continuously to form microspheres;
and continuously introducing the emulsion into a water reservoir which is less than about 15-20 times the volume of the cumulative volume of the emulsion, effective for extracting the ethyl acetate from the microspheres.
2. A process in accordance with claim 1 wherein the water reservoir is effective for extracting up to about 95% of the ethyl acetate from the microspheres.
3. A process in accordance with claim 1 wherein the two phase system is emulsified at approximately a 2:1 ratio of water to ethyl acetate.
4. A process in accordance with claim 2 wherein the lipophilic drug compound is selected from the group consisting of: avermectins, milbemycins, nodulisporic acid or a derivative thereof, fipronil and steroids.
5. A process in accordance with claim 1 wherein said emulsifying is comprised of adding an emulsifying agent selected from the group consisting of: poly(vinyl alcohol), Tween 80, polysorbates and poloxamers.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1278096P | 1996-03-04 | 1996-03-04 | |
GBGB9608930.5A GB9608930D0 (en) | 1996-04-29 | 1996-04-29 | Process for removing organic phase solvent from PLGA microspheres containing a lipophilic drug |
Publications (2)
Publication Number | Publication Date |
---|---|
GB9704186D0 GB9704186D0 (en) | 1997-04-16 |
GB2310801A true GB2310801A (en) | 1997-09-10 |
Family
ID=26309232
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB9704186A Withdrawn GB2310801A (en) | 1996-03-04 | 1997-02-28 | Process for removing an organic solvent from lactide-glycoside copolymer microspheres |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB2310801A (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999058112A1 (en) * | 1998-05-13 | 1999-11-18 | Microbiological Research Authority | Improvements relating to encapsulation of bioactive agents |
WO2000066087A2 (en) * | 1999-05-03 | 2000-11-09 | Southern Biosystems, Inc. | Emulsion-based processes for making microparticles |
US6270795B1 (en) | 1995-11-09 | 2001-08-07 | Microbiological Research Authority | Method of making microencapsulated DNA for vaccination and gene therapy |
WO2002019988A2 (en) * | 2000-09-05 | 2002-03-14 | Roland Bodmeier | Sustained release particle dispersion |
EP1197207A2 (en) * | 2000-10-10 | 2002-04-17 | American Cyanamid Company | Stable compositions for parenteral administration |
EP1230338A1 (en) * | 1999-11-19 | 2002-08-14 | Zycos Inc. | Continuous-flow method for preparing microparticles |
US6667294B2 (en) | 1995-11-09 | 2003-12-23 | Microbiological Research Authority | Microencapsulated DNA for vaccination and gene therapy |
WO2007119028A2 (en) * | 2006-04-19 | 2007-10-25 | Galderma S.A. | Composition including at least one aqueous phase and at least one fatty phase including ivermectin |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995011009A1 (en) * | 1993-10-22 | 1995-04-27 | Genentech, Inc. | Method for preparing microspheres comprising a fluidized bed drying step |
WO1995013799A1 (en) * | 1993-11-19 | 1995-05-26 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of biodegradable microparticles containing a biologically active agent |
-
1997
- 1997-02-28 GB GB9704186A patent/GB2310801A/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995011009A1 (en) * | 1993-10-22 | 1995-04-27 | Genentech, Inc. | Method for preparing microspheres comprising a fluidized bed drying step |
WO1995013799A1 (en) * | 1993-11-19 | 1995-05-26 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of biodegradable microparticles containing a biologically active agent |
Non-Patent Citations (1)
Title |
---|
Proc. Int. Symp. Controlled Bioact. Mater. Vol. 23 1996 Chern R T et. al. pages 363-364 * |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6743444B2 (en) | 1995-11-09 | 2004-06-01 | Microbiological Research Authority | Method of making microencapsulated DNA for vaccination and gene therapy |
US6667294B2 (en) | 1995-11-09 | 2003-12-23 | Microbiological Research Authority | Microencapsulated DNA for vaccination and gene therapy |
US6270795B1 (en) | 1995-11-09 | 2001-08-07 | Microbiological Research Authority | Method of making microencapsulated DNA for vaccination and gene therapy |
US6309569B1 (en) | 1998-05-13 | 2001-10-30 | Microbiological Research Authority | Encapsulation of bioactive agents |
WO1999058112A1 (en) * | 1998-05-13 | 1999-11-18 | Microbiological Research Authority | Improvements relating to encapsulation of bioactive agents |
US6440493B1 (en) | 1999-05-03 | 2002-08-27 | Southern Biosystems, Inc. | Emulsion-based processes for making microparticles |
WO2000066087A2 (en) * | 1999-05-03 | 2000-11-09 | Southern Biosystems, Inc. | Emulsion-based processes for making microparticles |
WO2000066087A3 (en) * | 1999-05-03 | 2001-06-21 | Southern Biosystems Inc | Emulsion-based processes for making microparticles |
US6291013B1 (en) | 1999-05-03 | 2001-09-18 | Southern Biosystems, Inc. | Emulsion-based processes for making microparticles |
EP1230338A1 (en) * | 1999-11-19 | 2002-08-14 | Zycos Inc. | Continuous-flow method for preparing microparticles |
EP1230338A4 (en) * | 1999-11-19 | 2004-03-31 | Zycos Inc | Continuous-flow method for preparing microparticles |
WO2002019988A3 (en) * | 2000-09-05 | 2002-06-27 | Roland Bodmeier | Sustained release particle dispersion |
WO2002019988A2 (en) * | 2000-09-05 | 2002-03-14 | Roland Bodmeier | Sustained release particle dispersion |
EP1197207A3 (en) * | 2000-10-10 | 2003-02-05 | American Cyanamid Company | Stable compositions for parenteral administration |
EP1197207A2 (en) * | 2000-10-10 | 2002-04-17 | American Cyanamid Company | Stable compositions for parenteral administration |
WO2007119028A2 (en) * | 2006-04-19 | 2007-10-25 | Galderma S.A. | Composition including at least one aqueous phase and at least one fatty phase including ivermectin |
FR2900052A1 (en) * | 2006-04-19 | 2007-10-26 | Galderma Sa | COMPOSITION COMPRISING AT LEAST ONE AQUEOUS PHASE AND AT LEAST ONE FATTY PHASE COMPRISING IVERMECTIN |
WO2007119028A3 (en) * | 2006-04-19 | 2008-04-03 | Galderma Sa | Composition including at least one aqueous phase and at least one fatty phase including ivermectin |
EP2374449A2 (en) * | 2006-04-19 | 2011-10-12 | Galderma S.A. | Composition including at least one aqueous phase and at least one oil phase including ivermectin |
EP2374449A3 (en) * | 2006-04-19 | 2012-02-29 | Galderma S.A. | Composition including at least one aqueous phase and at least one oil phase including ivermectin |
US8362069B2 (en) | 2006-04-19 | 2013-01-29 | Galderma S.A. | Compositions comprising at least one aqueous phase and at least one fatty phase which comprises avermectin compounds |
US9592249B2 (en) | 2006-04-19 | 2017-03-14 | Galderma S.A. | Compositions comprising at least one aqueous phase and at least one fatty phase which comprises avermectin compounds |
Also Published As
Publication number | Publication date |
---|---|
GB9704186D0 (en) | 1997-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100211435B1 (en) | Method for producing sustained release microsphere preparation | |
AU733199B2 (en) | Microparticles | |
US5650173A (en) | Preparation of biodegradable microparticles containing a biologically active agent | |
CA2074322C (en) | A composition for the sustained and controlled release of medicamentous substances and a process for preparing the same | |
FI76493B (en) | MIKROINKAPSLINGSFOERFARANDE. | |
EP1925297B2 (en) | Method for preparing microparticles having a selected polymer molecular weight | |
US5503851A (en) | Microencapsulation of water-soluble medicaments | |
FR2810885A1 (en) | Sustained release microparticles and their preparation using a multi-emulsion process, for delivery of drugs for up to 6 months or longer | |
Soppimath et al. | Ethyl acetate as a dispersing solvent in the production of poly (DL-lactide-co-glycolide) microspheres: effect of process parameters and polymer type | |
EP2327397A2 (en) | Method for manufacturing sustained release microsphere by solvent flow evaporation method | |
PL212531B1 (en) | Sustained-release composition and process for producing the same | |
EP1716847A1 (en) | Bioabsorbable pharmaceutical formulation comprising a PLGA copolymer | |
EP3178471B1 (en) | Preparation method of drug-containing sustained release microparticles | |
GB2310801A (en) | Process for removing an organic solvent from lactide-glycoside copolymer microspheres | |
EP1210942B1 (en) | Microparticles | |
WO1999033558A1 (en) | Method for producing an aqueous colloidal dispersion of nanoparticles | |
CA2123481C (en) | Process for the preparation of microballs and microballs thus obtained | |
CA2527994C (en) | Process for producing microparticles | |
CN111643483B (en) | Method for preparing galanthamine sustained-release microspheres | |
CN109939220A (en) | Polypeptide microballoon and preparation method thereof with quick-release and slow release effect | |
WO2001002087A1 (en) | Method for producing aqueous colloidal dispersions of nanoparticles | |
JP2006328060A (en) | Bioabsorbable pharmaceutical formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |